Építés alatt – nem éles oldal
Belépés

3112 open Tüdőrák trials worldwide. Travel and costs are your own unless the study pays them; ask the study team first.

OrszágOpen trials
Kína1145
Egyesült Államok901
Franciaország318
Spanyolország275
Olaszország274
All other countries

The same trial often runs in several countries

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4) has 3 sites in Szaúd-Arábia and runs in 35 countries. If a site near you is full, another one may still take people.

See A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4) in all 35 countries
Építés alatt, nem éles – Tüdőrák: vizsgálatok itt: Szaúd-Arábia – Frontlight Research